Clinical trials: Otorhinolaryngologic Neoplasms
Oropharyngeal Cancer
Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
Standard-of-care treatment options for oropharyngeal cancer often result in long-term side effects that interfere with normal quality of life.
- Trial name
- NCT02225496
- Testing
- Transoral Robotic Surgery (TORS), Modified Barium Swallow (MBS), Questionnaires
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer, Oropharyngeal Cancer
A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer
The goal of this clinical research study is to use computed tomography (CT) scans to measure and guide your radiation therapy. Researchers want to learn if the CT scans can be used to adapt radiation therapy to the changes in…
- Trial name
- NCT00490282
- Testing
- Intensity Modulated Radiation Therapy, Adaptive Radiotherapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Cancer
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
The purpose of this trial is to study the benefit of adjuvant chemotherapy using gemcitabine and cisplatin in high risk NPC patients with residual EBV DNA following primary radiotherapy with or without concurrent cisplatin.
- Trial name
- NCT00370890
- Testing
- Adjuvant chemotherapy (gemcitabine and cisplatin)
- Where
- 6 sites in Hong Kong
- Volunteers
- 104 people
- Sponsor
- Chinese University of Hong Kong
Nasopharyngeal Carcinoma (NPC)
Prognostic Value of TIL in Nasopharyngeal Carcinoma
Our center plans to conduct a prospective, multicenter, observational study aimed at observing the percentage of TIL infiltration calculated using deep learning methods based on digital pathological images, and analyzing its…
- Trial name
- NCT06763640
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase II trial studies the effect of cemiplimab in combination with low-dose paclitaxel and carboplatin in treating patients with squamous cell carcinoma of the head and neck that has come back (recurrent) or spread to other…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT04862650
- Testing
- Carboplatin, Cemiplimab, Paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Marcelo Bonomi
Head and Neck Neoplasms, Deglutition Disorders
EMST in Patients Undergoing CRT for HNCA
This study is a randomized trial examining the impact of expiratory muscle strength training (EMST) on maintenance of safe and efficient oropharyngeal swallow function in persons with cancer of the head and neck (HNCA) undergoing…
- Trial name
- NCT03916809
- Testing
- EMST
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Milwaukee
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
This pilot clinical trial studies transoral robotic surgery (TORS) in treating patients with benign or malignant tumors of the head and neck.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT01473784
- Testing
- transoral robotic surgery, quality of life assessment
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
To compare whether AK104 combined with GP or PFLL can improve survival benefit, safety and tolerability in nasopharyngeal carcinoma patients who have failed first-line treatment; To compare the survival benefits of GP or GFLL…
- Trial name
- NCT06241599
- Testing
- GP/PFLL+AK104
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Ototoxicity, Drug-Induced, Ototoxicity, Radiation-Induced
Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood
This study is aimed at people treated for cancer before the age of 25, who have been followed for at least 5 years, and who are now aged between 18 and 50. It is a prospective, multicenter, non-randomized study.
- Conditions
- Ototoxicity, Drug-Induced, Ototoxicity, Radiation-Induced, Pediatric Cancer
- Trial name
- RISP-OTOTOX (NCT06957132)
- Testing
- Audiogram
- Where
- 3 sites in France
- Volunteers
- 500 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): Oro-, Hypopharyngeal and Laryngeal Cancer
TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors
TPF-C-HIT investigates the combination of induction chemotherapy with TPF followed by radioimmunotherapy with cetuximab and IMRT plus carbon ion boost with regard to efficacy and toxicity of the combination regimen.
- Trial name
- TPF-C-HIT (NCT01245985)
- Testing
- carbon ion boost
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Heidelberg University
Oropharyngeal Dysphagia
REVIVE Prospective Registry Cohort Study
The main purpose of this registry is to collect observational, long-term safety and effectiveness data in participants who have received iltamiocel as part of the blinded portion of the REVIVE clinical study.
- Trial name
- NCT07429890
- Testing
- Other: No Intervention (subjects were previously treated with Iltamiocel). This is a observational study and all participants will be observed with no intervention.
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of California, Davis
Laryngeal Neoplasms, Pharyngeal Neoplasms
Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma
The aim of the study is to find for one or more serum or tissue markers of molecular biology in head and neck cancer patients used for early diagnosis, predicting prognosis and being sensitive to chemotherapy and radiotherapy
- Trial name
- NCT01171235
- Volunteers
- 200 people
- Sponsor
- Southern Medical University, China
Otitis Media With Effusion After Nasopharyngeal Carcinoma
A Prospective, Randomized, Controlled Clinical Study of BET Combined With Tympanostomy Tube Insertion in the Treatment of Intractable OME After Radiotherapy for NPC
The primary purpose of this study is to compare balloon Eustachian tuboplasty (BET) combined with tympanostomy tube insertion and simply tympanostomy tube insertion in the treatment of otitis media with effusion (OME) in…
- Trial name
- NCT05449184
- Testing
- Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion, Tympanostomy Tube Insertion
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Cancer
A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
Cisplatin or Carboplatin will be given on day 1 every 21 days for 6 cycles; Gemcitabine will be given on day 1 and day 8 every 21 days for 6 cycles.
- Trial name
- NCT00603915
- Testing
- Gemcitabine, Carboplatin/Cisplatin, erlotinib
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Head and Neck Cancer, Xerostomia
Xerostomia Pilot Fudan: Acupuncture for Prevention of Radiation-Induced Xerostomia
PRIMARY AIM 1. Determine the feasibility of providing true and sham acupuncture treatment to patients at Fudan University Cancer Hospital (Cancer Hospital) who are receiving radiation treatment for cancer of the head and/or neck…
- Trial name
- NCT00862550
- Testing
- Acupuncture
- Where
- China
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma
Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
Recurrence rate after curative treatment for locally advanced Nasopharyngeal carcinoma (NPC) is reported varying from 15% to 30% of cases, while approximately 5-11% of patients present with de novo metastatic disease.
- Trial name
- POINT (NCT04825990)
- Testing
- Pembrolizumab
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
HNSCC, Lip SCC
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembrolizumab and cetuximab for patients with recurrent/metastatic HNSCC.
- Conditions
- HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT03082534
- Testing
- Pembrolizumab, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of California, San Diego
Laryngeal Carcinoma, Quality of Life (QOL)
Quality of Life and Functional Outcomes in Laryngeal Cancer Patients
Laryngeal squamous cell carcinomas are head and neck malignancies that directly affect both swallowing and voice functions and are associated with a significant deterioration in patients' quality of life throughout the treatment…
- Conditions
- Laryngeal Carcinoma, Quality of Life (QOL), Patient Satisfaction, Voice Quality
- Trial name
- QoL in LSSC (NCT07320820)
- Testing
- Quality of Life Assessment, Patient Satisfaction Assessment, Swallowing Function Assessment
- Volunteers
- 120 people
- Sponsor
- Saglik Bilimleri Universitesi
Squamous Cell Carcinoma, Oropharynx Cancer
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
To learn if SAR444245 given in combination with cemiplimab can help to kill cancer cells in patients with HPV-related oropharynx cancer who are scheduled to have surgery to remove the disease
- Conditions
- Squamous Cell Carcinoma, Oropharynx Cancer, Head and Neck Cancer
- Trial name
- NCT05535023
- Testing
- SAR444245, Cemiplimab
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Epstein-Barr Virus Infections
Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations
This study will evaluate the ability of people of different ethnic backgrounds to develop immune responses against the Epstein-Barr virus (EBV).
- Trial name
- NCT00070785
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.